Skip to main content

Research Repository

Advanced Search

The future of EPAC-targeted therapies: Agonism versus antagonism

Parnell, Euan; Palmer, Timothy M.; Yarwood, Stephen J.

Authors

Euan Parnell

Stephen J. Yarwood



Abstract

Pharmaceutical manipulation of cAMP levels exerts beneficial effects through the regulation of the exchange protein activated by cAMP (EPAC) and protein kinase A (PKA) signalling routes. Recent attention has turned to the specific regulation of EPAC isoforms (EPAC1 and EPAC2) as a more targeted approach to cAMP-based therapies. For example, EPAC2-selective agonists could promote insulin secretion from pancreatic β cells, whereas EPAC1-selective agonists may be useful in the treatment of vascular inflammation. By contrast, EPAC1 and EPAC2 antagonists could both be useful in the treatment of heart failure. Here we discuss whether the best way forward is to design EPAC-selective agonists or antagonists and the current strategies being used to develop isoform-selective, small-molecule regulators of EPAC1 and EPAC2 activity.

Citation

Parnell, E., Palmer, T. M., & Yarwood, S. J. (2015). The future of EPAC-targeted therapies: Agonism versus antagonism. Trends in Pharmacological Sciences, 36(4), 203-214. https://doi.org/10.1016/j.tips.2015.02.003

Journal Article Type Review
Acceptance Date Mar 2, 2015
Online Publication Date Mar 3, 2018
Publication Date Apr 1, 2015
Deposit Date Oct 30, 2018
Publicly Available Date Oct 31, 2018
Journal Trends in Pharmacological Sciences
Print ISSN 0165-6147
Electronic ISSN 1873-3735
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 36
Issue 4
Pages 203-214
DOI https://doi.org/10.1016/j.tips.2015.02.003
Keywords Toxicology; Pharmacology; EPAC; cAMP; Inflammation; Diabetes; Agonism; Antagonism
Public URL https://hull-repository.worktribe.com/output/1137533
Publisher URL https://www.sciencedirect.com/science/article/pii/S016561471500022X?via%3Dihub
Additional Information This article is maintained by: Elsevier; Article Title: The future of EPAC-targeted therapies: agonism versus antagonism; Journal Title: Trends in Pharmacological Sciences; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.tips.2015.02.003; Content Type: article; Copyright: Copyright © 2015 The Authors. Published by Elsevier Ltd.

Files

Article (2.4 Mb)
PDF

Copyright Statement
This work is licensed under a Creative Commons Attribution 4.0 International License.





You might also like



Downloadable Citations